Loading...

InventionMed

WSE:INM
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
INM
WSE
PLN69M
Market Cap
  1. Home
  2. PL
  3. Healthcare
Company description

InventionMed S.A. focuses on the development of medical simulators based on VR technology for use in education in esthetic and clinical dermatology. The last earnings update was 95 days ago. More info.


Add to Portfolio Compare Print
  • InventionMed has significant price volatility in the past 3 months.
INM Share Price and Events
7 Day Returns
17.1%
WSE:INM
-1.7%
PL Medical Equipment
-0.9%
PL Market
1 Year Returns
0%
WSE:INM
-43.5%
PL Medical Equipment
-7.4%
PL Market
INM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
InventionMed (INM) 17.1% 11.6% 26.3% 0% 269.2% -36.8%
PL Medical Equipment -1.7% -4.2% -16.5% -43.5% -75.2% -82.6%
PL Market -0.9% -7.1% -6.3% -7.4% 9.6% -11.5%
1 Year Return vs Industry and Market
  • INM outperformed the Medical Equipment industry which returned -43.5% over the past year.
  • INM outperformed the Market in Poland which returned -7.4% over the past year.
Price Volatility
INM
Industry
5yr Volatility vs Market

INM Value

 Is InventionMed undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of InventionMed to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for InventionMed.

WSE:INM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.5%
Perpetual Growth Rate 10-Year PL Government Bond Rate 2.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for WSE:INM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PL Govt Bond Rate 2.9%
Equity Risk Premium S&P Global 7.1%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.9
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.895 (1 + (1- 19%) (0%))
0.93
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.85% + (0.93 * 7.14%)
9.49%

Discounted Cash Flow Calculation for WSE:INM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for InventionMed is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

WSE:INM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (PLN, Millions) Source Present Value
Discounted (@ 9.49%)
2019 0.60 Est @ 5.98% 0.55
2020 0.63 Est @ 5.04% 0.53
2021 0.66 Est @ 4.38% 0.50
2022 0.68 Est @ 3.92% 0.48
2023 0.71 Est @ 3.6% 0.45
2024 0.73 Est @ 3.38% 0.43
2025 0.76 Est @ 3.22% 0.40
2026 0.78 Est @ 3.11% 0.38
2027 0.80 Est @ 3.03% 0.36
2028 0.83 Est @ 2.98% 0.33
Present value of next 10 years cash flows PLN4.39
WSE:INM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= PLN0.83 × (1 + 2.85%) ÷ (9.49% – 2.85%)
PLN12.81
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= PLN12.81 ÷ (1 + 9.49%)10
PLN5.17
WSE:INM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= PLN4.39 + PLN5.17
PLN9.57
Equity Value per Share
(PLN)
= Total value / Shares Outstanding
= PLN9.57 / 142.79
PLN0.07
WSE:INM Discount to Share Price
Calculation Result
Value per share (PLN) From above. PLN0.07
Current discount Discount to share price of PLN0.48
= -1 x (PLN0.48 - PLN0.07) / PLN0.07
-616.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of InventionMed is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for InventionMed's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are InventionMed's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:INM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in PLN PLN-0.01
WSE:INM Share Price ** WSE (2019-05-20) in PLN PLN0.48
Europe Medical Equipment Industry PE Ratio Median Figure of 56 Publicly-Listed Medical Equipment Companies 31.26x
Poland Market PE Ratio Median Figure of 463 Publicly-Listed Companies 10.7x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of InventionMed.

WSE:INM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:INM Share Price ÷ EPS (both in PLN)

= 0.48 ÷ -0.01

-81.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • InventionMed is loss making, we can't compare its value to the Europe Medical Equipment industry average.
  • InventionMed is loss making, we can't compare the value of its earnings to the Poland market.
Price based on expected Growth
Does InventionMed's expected growth come at a high price?
Raw Data
WSE:INM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -81.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Medical Equipment Industry PEG Ratio Median Figure of 39 Publicly-Listed Medical Equipment Companies 2.5x
Poland Market PEG Ratio Median Figure of 113 Publicly-Listed Companies 0.93x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for InventionMed, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on InventionMed's assets?
Raw Data
WSE:INM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in PLN PLN0.10
WSE:INM Share Price * WSE (2019-05-20) in PLN PLN0.48
Poland Medical Equipment Industry PB Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 1.12x
Poland Market PB Ratio Median Figure of 689 Publicly-Listed Companies 0.97x
WSE:INM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:INM Share Price ÷ Book Value per Share (both in PLN)

= 0.48 ÷ 0.10

4.82x

* Primary Listing of InventionMed.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • InventionMed is overvalued based on assets compared to the PL Medical Equipment industry average.
X
Value checks
We assess InventionMed's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. InventionMed has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

INM Future Performance

 How is InventionMed expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InventionMed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is InventionMed expected to grow at an attractive rate?
  • Unable to compare InventionMed's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare InventionMed's earnings growth to the Poland market average as no estimate data is available.
  • Unable to compare InventionMed's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
WSE:INM Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 19%
Europe Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
Poland Market Earnings Growth Rate Market Cap Weighted Average 10%
Poland Market Revenue Growth Rate Market Cap Weighted Average 5.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:INM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:INM Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2018-12-31 -1 -1
2018-09-30 0 0 -1
2018-06-30 1 0 0
2018-03-31 1 0 0
2017-12-31 1 1 0
2017-09-30 1 0 1
2017-06-30 0 0 0
2017-03-31 0 0 0
2016-12-31 0 0 0
2016-09-30 0 0 0
2016-06-30 0 0 0
2016-03-31 1 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if InventionMed is high growth as no earnings estimate data is available.
  • Unable to determine if InventionMed is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:INM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from InventionMed Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:INM Past Financials Data
Date (Data in PLN Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00
2016-06-30 0.00
2016-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if InventionMed will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine InventionMed's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. InventionMed's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. InventionMed's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess InventionMed's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
InventionMed has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

INM Past Performance

  How has InventionMed performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare InventionMed's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • InventionMed does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare InventionMed's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare InventionMed's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
InventionMed's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from InventionMed Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:INM Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -0.84 0.20
2018-09-30 -0.01 -0.98 0.17
2018-06-30 0.84 -0.20 0.13
2018-03-31 0.84 0.24 0.10
2017-12-31 0.84 0.33 0.06
2017-09-30 0.85 0.50 0.05
2017-06-30 0.00 -0.25 0.04
2017-03-31 0.00 -0.32 0.04
2016-12-31 0.00 -0.43 0.04
2016-09-30 -0.02 -0.29 0.04
2016-06-30 0.15 -0.29 0.04
2016-03-31 0.61 -0.51 0.04
2015-12-31 0.66 -8.82 0.04
2015-09-30 0.75 -8.90 0.04
2015-06-30 0.67 -3.80 0.04
2015-03-31 0.27 -1.28 0.04
2014-12-31 0.22 6.91 0.04
2014-09-30 0.32 7.93 0.04
2014-06-30 0.23 3.82 0.05
2014-03-31 0.28 0.77 0.05
2013-12-31 0.36 1.47 0.06
2013-09-30 0.32 0.48 0.05
2013-06-30 0.44 -0.44 0.04
2013-03-31 0.46 0.48 0.02
2012-12-31 0.52 0.13 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if InventionMed has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if InventionMed has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if InventionMed improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess InventionMed's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
InventionMed has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

INM Health

 How is InventionMed's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up InventionMed's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • InventionMed's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • InventionMed's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of InventionMed's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • InventionMed has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from InventionMed Company Filings, last reported 4 months ago.

WSE:INM Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 14.23 0.00
2018-09-30 14.37 0.00
2018-06-30 14.48 0.00
2018-03-31 14.87 0.00
2017-12-31 11.07 0.05 6.14
2017-09-30 11.34 0.05
2017-06-30 10.67 0.05
2017-03-31 10.70 0.05
2016-12-31 10.74 0.13 10.09
2016-09-30 10.84 0.13
2016-06-30 10.92 0.13
2016-03-31 11.02 0.13
2015-12-31 11.17 0.20 10.10
2015-09-30 1.37 0.51
2015-06-30 1.45 0.38
2015-03-31 1.77 0.38
2014-12-31 10.23 0.63 0.51
2014-09-30 9.51 0.00
2014-06-30 4.48 0.00
2014-03-31 2.28 0.00
2013-12-31 2.55 0.29 0.25
2013-09-30 1.58 0.00
2013-06-30 0.66 0.00 0.06
2013-03-31 1.51 0.00 0.13
2012-12-31 1.09 0.10 0.13
  • InventionMed has no debt.
  • InventionMed has no debt compared to 5 years ago when it was 11.4%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • InventionMed has sufficient cash runway for more than 3 years based on current free cash flow.
  • InventionMed has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -42.2% each year.
X
Financial health checks
We assess InventionMed's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. InventionMed has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

INM Dividends

 What is InventionMed's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from InventionMed dividends.
If you bought PLN2,000 of InventionMed shares you are expected to receive PLN0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate InventionMed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate InventionMed's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:INM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.5%
Poland Market Average Dividend Yield Market Cap Weighted Average of 200 Stocks 4.1%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.5%
Poland Bottom 25% Dividend Yield 25th Percentile 2.8%
Poland Top 25% Dividend Yield 75th Percentile 7.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as InventionMed has not reported any payouts.
  • Unable to verify if InventionMed's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of InventionMed's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as InventionMed has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess InventionMed's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can InventionMed afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. InventionMed has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

INM Management

 What is the CEO of InventionMed's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tomasz Kierul
CEO Bio

Mr. Tomasz Kierul serves as the Chief Executive Officer and President of Management Board at Inventionmed SA.

CEO Compensation
  • Insufficient data for Tomasz to compare compensation growth.
  • Insufficient data for Tomasz to establish whether their remuneration is reasonable compared to companies of similar size in Poland.
Management Team

Tomasz Kierul

TITLE
President of Management Board & CEO

Cezary Jasinski

TITLE
Vice President of Management Board
Board of Directors

Przemyslaw Romanowicz

TITLE
Chairwoman of Supervisory Board

Aleksander Szalecki

TITLE
Member of the Supervisory Board
TENURE
3.7 yrs

Barbara Zegarska

TITLE
Supervisory Board Member

Lidia Rudnicka

TITLE
Member of Supervisory Board

Martin Daliga

TITLE
Member of Supervisory Board

Jan Trzcinski

TITLE
Member of Supervisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess InventionMed's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. InventionMed has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

INM News

Simply Wall St News

Interested In Inventionmed SA (WSE:INM)? Here's How It Performed Recently

In this article, I will take a look at Inventionmed SA's (WSE:INM) most recent earnings update (31 March 2018) and compare these latest figures against its performance over the past few years, along with how the rest of INM's industry performed. … How Did INM's Recent Performance Stack Up Against Its Past. … INM recently turned a profit of zł236.02k (most recent trailing twelve-months) compared to its average loss of -zł79.30k over the past five years

Simply Wall St -

Does Inventionmed SA (WSE:INM) Go Up With The Market?

Based on this beta value, INM appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … This is an interesting conclusion, since both INM’s size and industry indicates the stock should have a higher beta than it currently has. … I test INM’s ratio of fixed assets to total assets in order to determine how high the risk is associated with this type of constraint.

Simply Wall St -

Does Inventionmed SA's (WSE:INM) PE Ratio Warrant A Sell?

Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for INM Price per share = PLN0.69 Earnings per share = PLN0.004 ∴ Price-Earnings Ratio = PLN0.69 ÷ PLN0.004 = 181.4x The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. … Since INM's P/E of 181.4x is higher than its industry peers (13.6x), it means that investors are paying more than they should for each dollar of INM's earnings. … For example, if you accidentally compared lower growth firms with INM, then INM’s P/E would naturally be higher since investors would reward INM’s higher growth with a higher price.

Simply Wall St -

INM Company Info

Description

InventionMed S.A. focuses on the development of medical simulators based on VR technology for use in education in esthetic and clinical dermatology. Its flagship project is TutorDerm, a simulator and an application that lets users perform essential procedures needed for the treatment of specific skin aliments. InventionMed S.A. was founded in 2009 and is based in Bydgoszcz, Poland. InventionMed S.A. is a subsidiary of Joyfix Limited.

Details
Name: InventionMed S.A.
INM
Exchange: WSE
Founded: 2009
PLN68,537,835
142,787,157
Website: http://inventionmed.com
Address: InventionMed S.A.
ul. Bydgoskich Przemyslowców 6,
Bydgoszcz,
85-862,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE INM Common Bearer Shares Warsaw Stock Exchange PL PLN 25. Mar 2013
Number of employees
Current staff
Staff numbers
0
InventionMed employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 21:52
End of day share price update: 2019/05/20 00:00
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.